For press inquiries click here to contact us.
Turning Point Therapeutics
How Turning Point Therapeutics became a 2019 IPO standout
Lyell Immunopharma
Exclusive: GSK’s Hal Barron allies with Rick Klausner’s $600M cell therapy startup, looking to break new ground blitzing solid tumors
insitro
Coursera Cofounder Daphne Koller Melds AI And Biology In Drug Startup Insitro
Aimmune Therapeutics, Inc.
It’s not perfect, but it’s a good start: FDA panelists largely endorse Aimmune’s peanut allergy therapy
10x Genomics
10x Genomics’ IPO rockets past a $390M raise
Venatorx Pharmaceuticals, Inc.
VC-backed VenatoRx beefs up team with three new hires
Oric Pharmaceuticals, Inc.
New exec team, new money and a big syndicate — ORIC heads to PhII
insitro
Biotech Insitro boosts executive team with Aimmune development chief and Pfizer vet
Adaptive Biotechnologies Corporation
Adaptive Biotechnologies stock soars 90% after ringing Nasdaq opening bell following $300M IPO
Please see important disclaimers in the Terms section.